STOCK TITAN

Palatin Technologies, Inc. - PTN STOCK NEWS

Welcome to our dedicated page for Palatin Technologies news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies stock.

Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company based in Cranbury, New Jersey. The company focuses on developing first-in-class medicines that target the melanocortin and natriuretic peptide receptor systems. These therapies are aimed at treating a variety of diseases with significant unmet medical needs and commercial potential.

The company's lead product is Vyleesi, a melanocortin receptor agonist for premenopausal women suffering from hypoactive sexual desire disorder (HSDD). Recently, Palatin announced the divestiture of Vyleesi to better focus on its robust development and clinical pipeline.

Palatin is also advancing several promising candidates through clinical trials:

  • PL9643: A melanocortin receptor agonist for treating dry eye disease (DED). The company recently reported successful results from its Phase 3 MELODY-1 trial, demonstrating significant efficacy and safety.
  • PL8177: This selective melanocortin receptor 1 (MC1R) agonist peptide has completed Phase 1 trials for inflammatory bowel diseases and systemic non-infectious uveitis. It is being further developed for treating COVID-19.
  • PL3994: A natriuretic peptide receptor (NPR)-A agonist aimed at treating cardiovascular diseases and other conditions.

Palatin’s strategic focus is on developing targeted, receptor-specific product candidates and forming marketing collaborations with industry leaders to maximize their commercial potential. The company's research and development efforts are guided by a commitment to innovative science and a focus on areas with high probability of success and differentiation.

Financially, Palatin has shown strong operational progress. As of the latest fiscal quarter, the company announced a substantial cash position, ensuring the funding of its ongoing projects into the second half of 2024. The company's leadership believes that their internal research and development efforts, concentrating on melanocortin receptor-based therapies, hold significant promise for the treatment of various conditions, including obesity and erectile dysfunction.

Palatin’s approach to biopharmaceutical development underscores a commitment to addressing significant medical needs through innovative receptor-specific therapies. For more information, visit www.Palatin.com and follow them on Twitter at @PalatinTech.

Rhea-AI Summary
Palatin Technologies to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences
-
Rhea-AI Summary
Palatin Technologies, Inc. completes enrollment of 570 patients in the PL9643 MELODY-1 Phase 3 study for dry eye disease (DED). Topline data expected by late 4Q 2023. Interim analysis of first 120 patients shows excellent safety and tolerability. PL9643 has potential to address multiple signs and symptoms of DED.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) has initiated a clinical development program for bremelanotide, a melanocortin receptor 4 (MCR4) agonist, co-formulated with a PDE5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy. The company aims to address the unmet medical needs of the 30%-40% of ED patients who do not respond to current PDE5i treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
Rhea-AI Summary
Palatin Technologies announces first sale of Vyleesi in China and completion of Phase 3 trial in South Korea for HSDD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
-
Rhea-AI Summary
Palatin Technologies enters strategic partnership with UpScriptHealth to increase access to Vyleesi for patients with hypoactive sexual desire disorder (HSDD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.86%
Tags
partnership
-
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) to participate in Canaccord Genuity 43rd Annual Growth Conference. The company will join an Analyst led Fireside Chat on August 9, 2023, at 5:00 p.m. ET. A live webcast will be accessible on the Investors section of Palatin's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
Rhea-AI Summary
Palatin Technologies announces preliminary fiscal fourth quarter results for Vyleesi product revenue, with significant growth in key operating metrics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Palatin Technologies, Inc. announces financial results for Q3 2023, highlighting positive data from Phase 3 PL9643 clinical study for dry eye disease and growth in Vyleesi net product revenue
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
Rhea-AI Summary
Palatin Technologies, Inc. will announce its Q3 fiscal year 2023 operating results on May 16, 2023. A conference call and live webcast will be held to review the results and provide updates on programs under development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings

FAQ

What is the current stock price of Palatin Technologies (PTN)?

The current stock price of Palatin Technologies (PTN) is $0.93 as of November 19, 2024.

What is the market cap of Palatin Technologies (PTN)?

The market cap of Palatin Technologies (PTN) is approximately 17.9M.

What is Palatin Technologies' lead product?

Palatin Technologies' lead product is Vyleesi, a melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

What are Palatin Technologies' main areas of focus?

Palatin focuses on developing first-in-class medicines for diseases with significant unmet medical needs, specifically targeting the melanocortin and natriuretic peptide receptor systems.

What is PL9643, and what is it used for?

PL9643 is a melanocortin receptor agonist developed by Palatin Technologies for treating dry eye disease (DED). It has shown significant efficacy and safety in Phase 3 clinical trials.

What other products are in Palatin Technologies' pipeline?

Palatin is developing several other products, including PL8177 for inflammatory bowel diseases and COVID-19, and PL3994 for treating cardiovascular diseases.

What recent financial highlights has Palatin Technologies announced?

Palatin announced a strong cash position as of their latest fiscal quarter, ensuring the funding of ongoing projects into the second half of 2024.

How does Palatin Technologies plan to maximize the commercial potential of its products?

Palatin plans to form marketing collaborations with industry leaders to maximize the commercial potential of its targeted, receptor-specific product candidates.

What are some recent achievements of Palatin Technologies?

Recent achievements include successful Phase 3 trial results for PL9643 in treating dry eye disease and the divestiture of Vyleesi to focus on their clinical pipeline.

What is the significance of melanocortin receptor agonists in Palatin's research?

Melanocortin receptor agonists, which Palatin specializes in, have effects on inflammation, immune responses, metabolism, food intake, and sexual function, making them significant for various treatments.

What partnerships has Palatin Technologies formed?

Palatin’s strategy includes forming collaborations with industry leaders to maximize the commercial potential of its products, though specific partners are not mentioned in the latest updates.

How can one learn more about Palatin Technologies?

For more information, visit Palatin's website at www.Palatin.com and follow them on Twitter at @PalatinTech.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Stock Data

17.95M
18.86M
3.5%
7.88%
5.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CRANBURY